• Home
  • About
  • Capabilities
  • R&D
  • Investors
  • News
  • Careers
简 繁
  • Home
  • About
  • Capabilities
  • R & D
  • Investors
  • News
  • Careers
Mabwell Signed an Agreement with Junshi Biosciences

Release time:Aug 28, 2017

The "Recombinant Human Anti-TNF-α Monoclonal Antibody Injection Cooperative Development Agreement" was signed with Shanghai Junshi Bio-pharmaceutical Co., Ltd. to jointly conduct preclinical research of a recombinant human anti-TNF-α monoclonal antibody injection.

Hot News
  • EHA 2026 | Mabwell Presents Latest Clinical Results of Novel Anti-TMPRSS6 Monoclonal Antibody 9MW3011
  • Mabwell’s LILRB4/CD3 targeting TCE Bispecific Antibody 6MW5311 Receives FDA Clearance for Clinical Trial Application
  • Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
  • Mabwell’s Subsidiary Myvision Appears at Retina China 2026
  • Highlights in Oral Presentation of Mabwell's 9MW2821 at 2026 ASCO
  • Press Conference on Early Diagnosis and Clinical Translation of Parkinson’s Disease & SST001 Clinical Trial Initiation Meeting Successfully Held
  • About Who We Are Leadership Milestone Awards Contact
  • Capabilities R&D Manufacturing Commericalization
  • R&D Products Pipeline High-tech Platforms R&D Progress
  • Investors Stock Information Announcements & Notices Financial Report Corporate Governance IR Contact
  • News Press Release
  • Careers Value Awards & Welfare

Follow us
on WeChat

Copyright ©2022 Mabwell (Shanghai) Bioscience Co., Ltd. 沪 ICP 备 17041957 号 Shanghai public network security:31011502008788

Legal Statement| Privacy Policy| 技术支持:予尚网络